CVS Health Corporation
CVS Health Corporation (CVS) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for CVS Health Corporation (CVS), featuring income statements, balance sheets, and cash flow data.
CVS Health Corporation (CVS) Income Statement & Financial Overview
Analyze CVS Health Corporation’s CVS earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $94.59B | $97.71B | $95.43B | $91.23B |
| Cost of Revenue | $80.19B | $84.81B | $82.87B | $77.85B |
| Gross Profit | $14.40B | $12.90B | $12.56B | $13.38B |
| Gross Profit Ratio | $0.15 | $0.13 | $0.13 | $0.15 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Expenses | $11.02B | $10.53B | $11.73B | $10.34B |
| Total Costs & Expenses | $91.21B | $95.34B | $94.60B | $88.19B |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $785.00M | $758.00M | $752.00M | $732.00M |
| Depreciation & Amortization | $1.15B | $1.15B | $1.16B | $1.15B |
| EBITDA | $4.56B | $4.03B | $2.02B | $4.22B |
| EBITDA Ratio | $0.05 | $0.04 | $0.02 | $0.05 |
| Operating Income | $3.37B | $2.37B | $832.00M | $3.04B |
| Operating Income Ratio | $0.04 | $0.02 | $0.009 | $0.03 |
| Other Income/Expenses (Net) | -$757.00M | -$242.00M | -$727.00M | -$708.00M |
| Income Before Tax | $2.62B | $2.13B | $105.00M | $2.34B |
| Income Before Tax Ratio | $0.03 | $0.02 | $0.001 | $0.03 |
| Income Tax Expense | $835.00M | $503.00M | $34.00M | $569.00M |
| Net Income | $1.78B | $1.64B | $87.00M | $1.77B |
| Net Income Ratio | $0.02 | $0.02 | $0.001 | $0.02 |
| EPS | $1.41 | $1.31 | $0.07 | $1.41 |
| Diluted EPS | $1.41 | $1.30 | $0.07 | $1.41 |
| Weighted Avg Shares Outstanding | $1.26B | $1.26B | $1.26B | $1.26B |
| Weighted Avg Shares Outstanding (Diluted) | $1.26B | $1.26B | $1.26B | $1.26B |
Over the last four quarters, CVS Health Corporation achieved steady financial progress, growing revenue from $91.23B in Q2 2024 to $94.59B in Q1 2025. Gross profit stayed firm with margins at 15% in Q1 2025 versus 15% in Q2 2024. Operating income totaled $3.37B in Q1 2025, maintaining a 4% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $4.56B. Net income rose to $1.78B, with EPS at $1.41. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan